CN112433053A - Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit - Google Patents
Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit Download PDFInfo
- Publication number
- CN112433053A CN112433053A CN202011311801.1A CN202011311801A CN112433053A CN 112433053 A CN112433053 A CN 112433053A CN 202011311801 A CN202011311801 A CN 202011311801A CN 112433053 A CN112433053 A CN 112433053A
- Authority
- CN
- China
- Prior art keywords
- protein
- reagent
- lung cancer
- detecting
- tetraspin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 48
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 48
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 48
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 47
- 238000012216 screening Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000002331 protein detection Methods 0.000 title abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 210000001808 exosome Anatomy 0.000 claims abstract description 28
- 102100024995 Tetraspanin-14 Human genes 0.000 claims description 14
- 101710133619 Tetraspanin-14 Proteins 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 102000036664 ADAM10 Human genes 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the field of in-vitro diagnostic reagents, in particular to an application of a Tetrasmanin-14 protein detection reagent in preparation of a lung cancer screening kit. The invention discovers for the first time that the level of Tetrasmanin-14 protein in plasma exosome of lung cancer patient is obviously higher than that of healthy people. According to the invention, the reagent for detecting the Tetraspin-14 protein is used for preparing the lung cancer screening kit, so that the effective screening of the lung cancer can be realized.
Description
Technical Field
The invention relates to the field of in-vitro diagnostic reagents, in particular to an application of a Tetrasmanin-14 protein detection reagent in preparation of a lung cancer screening kit.
Background
Lung cancer is one of the most common malignant tumors in the world, the morbidity and mortality of the lung cancer are on the rising trend year by year, the morbidity is at the top of the world at present, and the health and the life of human beings are seriously threatened.
The lung cancer is a disease good in occult, clinical symptoms are often shown only when the disease develops to the advanced stage, 70-80% of lung cancer patients are already at the middle and advanced stages when the lung cancer symptoms are diagnosed, cancer cells are diffused, the best curing time is missed, and the five-year survival rate is low. For early-stage lung cancer patients, the survival rate and the survival quality of the patients can be greatly improved by 5 years and more through timely treatment. Early diagnosis of lung cancer and effective screening are therefore of paramount importance.
The screening of the lung cancer refers to that the conventional physical examination is carried out on people without lung cancer related symptoms, and the lung cancer is found in time before the symptoms appear. If the lung cancer molecular marker in the plasma can be found, the molecular marker has important significance for prompting a clinician to take relevant treatment measures or decisions for a patient at an early stage.
The Tetraspanin-14 protein (Uniprot code: Q8NG11) is responsible for regulating ADAM 10-mediated GP6 and CDH 5.
No prior art related to lung cancer of Tetraspan-14 protein is found at present.
Disclosure of Invention
The invention aims to provide a novel lung cancer marker and application of a detection reagent of the marker in preparation of a lung cancer screening kit.
The technical scheme of the invention comprises the following steps:
application of a reagent for detecting Tetraspin-14 protein in preparation of a lung cancer screening kit.
As the application, the reagent for detecting the Tetraspin-14 protein is a reagent for enzyme-linked immunosorbent assay.
As the application, the reagent for detecting the Tetraspin-14 protein is a western blot reagent.
As mentioned above, the reagent for detecting the Tetraspin-14 protein is a reagent for a protein chip detection method.
As the aforementioned use, the reagent for detecting the Tetraspin-14 protein is a reagent for detecting the Tetraspin-14 protein in human plasma exosomes.
A lung cancer screening kit comprises a reagent for detecting Tetrasmanin-14 protein.
As the kit, the reagent for detecting the Tetraspin-14 protein is a reagent for enzyme-linked immunosorbent assay.
As the kit, the reagent for detecting the Tetraspin-14 protein is a western blot reagent.
As the kit, the reagent for detecting the Tetraspin-14 protein is a reagent for a protein chip detection method.
As the kit, the reagent for detecting the Tetraspin-14 protein is a reagent for detecting the Tetraspin-14 protein in human plasma exosome.
The key point of the invention is that the content of the Tetrasmanin-14 protein in human plasma exosomes is determined to be obviously related to the risk of suffering from lung cancer, so that the risk of suffering from lung cancer can be judged by detecting the content of the Tetrasmanin-14 protein in the human plasma exosomes, various means disclosed in the prior art can be adopted as a means for specifically detecting the Tetrasmanin-14 protein in the human plasma exosomes, and an enzyme-linked immunoassay method (protein chip) is specifically adopted for detection in the embodiment of the invention, but the method is not limited to the means, and any method capable of detecting the content of the Tetrasmanin-14 protein can be used for lung cancer screening.
The invention provides a new lung cancer screening marker and a new lung cancer screening kit, which can realize effective screening of lung cancer; and the plasma exosome can be used as a detection sample, so that the harm to a patient is low. The invention has good application prospect.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The foregoing aspects of the present invention are explained in further detail below with reference to specific embodiments. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1: comparison of Tetraspan-14 protein levels in lung cancer patients (LC), healthy control (NC) plasma exosomes.
FIG. 2: lung cancer patients (LC) were analyzed by ROC with healthy controls (NC).
Detailed Description
Example 1 relationship between Tetrasmanin-14 protein in plasma exosomes and Lung cancer
First, clinical data
40 lung cancer patients and 40 healthy controls were selected, and the basic information was as follows:
| basic information | Patients with lung cancer | Healthy controls |
| Number of |
40 | 40 |
| Age (age) | 58.8±11.5 | 50.1±14.3 |
| Proportion of male | 33(82.5％) | 17(42.5％) |
Second, detection principle
The method is the same as the basic enzyme-linked immunosorbent assay (ELISA) detection method.
A Tetraspanin-14 protein antibody (VVNTQCGYDVR amino acid sequence for specifically recognizing the Tetraspanin-14 protein) is fixed on the protein chip, and after the protein chip is incubated with plasma exosome protein, if the Tetraspanin-14 protein exists in the exosome protein, the Tetraspanin-14 protein can be bound; washing to remove unbound antibodies and other proteins, binding the fluorescent-labeled Tetraspin-14 protein antibody to the Tetraspin-14 protein for detection, and reading a signal by a fluorescence scanner, wherein the strength of the signal is in positive correlation with the affinity and the quantity of the antibody.
SEQ ID NO.1：VVNTQCGYDVR
Third, method
1. The preparation method of the plasma exosome protein comprises the following steps:
the sample was removed from-80 ℃ and centrifuged at 12000g for 15 minutes at 4 ℃ and the supernatant was transferred to a new centrifuge tube and filtered through a 0.22. mu.M microporous membrane, and then the exosomes were isolated using PTM-EVs kit manufactured by PTM corporation according to the instructions. Adding Urea with a final concentration of 8M and protease inhibitor for ultrasonic cleavage, and using a BCA kit for protein concentration determination.
2. Detection of Tetraspin-14 protein in plasma exosomes
The reagents used in this section were as follows:
the method comprises the following specific steps:
1) rewarming: taking out the chip from a refrigerator at-80 deg.C, putting in a refrigerator at 4 deg.C for rewarming for half an hour, and then putting in room temperature for rewarming for 15 min;
2) and (3) sealing: fixing 14 blocks in the rewarming chip, adding sealing liquid into each block after fixing, placing on a side swing bed, and sealing at room temperature for 3 hr;
3) incubation of plasma exosome protein samples: after the sealing is finished, pouring the sealing liquid completely, then quickly adding the prepared plasma exosome protein incubation liquid, wherein the sample loading volume is 200 mu L, and incubating overnight at 4 ℃ by laterally swinging a shaker at 20rpm (diluting the plasma exosome protein and the incubation liquid in a ratio of 1: 50 to obtain the plasma exosome protein incubation liquid);
4) cleaning: taking out the chip and the chip fence together, sucking out the sample, then quickly adding PBST with the same volume, and circulating for several times to ensure that no cross contamination exists among plasma exosome protein samples when the chip fence is detached. After the chip fence is removed, the chip is placed in a chip cleaning box with cleaning solution, and is cleaned for 3 times (10 min each time) by a horizontal shaking table at room temperature of 80 rpm;
5) and (3) secondary antibody incubation: transferring the chip into an incubation box added with 3mL of secondary antibody incubation liquid, laterally swinging a shaker at 40rpm, keeping out of the sun, and keeping at room temperature for 1 hr;
6) cleaning: the chip was removed (note that the upper surface of the chip was not touched or scratched), and placed in a chip washing cassette containing a washing solution, and washed 3 times 10min each time, on a horizontal shaker at room temperature and 80 rpm. After completion with ddH2O cleaning for 2 times, 10min each time;
7) drying;
8) scanning: scanning by using a crystal core LuxScan 10K microarray chip scanner;
9) data extraction: opening the corresponding GAL file (recording the position of protein in the chip), aligning the chip image and each array of the GAL file integrally, pressing an automatic alignment button, extracting data and storing.
Fourthly, the result
The mean expression level of the Tetraspin-14 protein in plasma exosomes of lung cancer patients was 1.57 (protein-to-quantitative ratio), and the mean expression level of the healthy control Tetraspin-14 protein was 0.61. The lung cancer group was statistically significant compared to healthy controls (p <0.01) (fig. 1). The lung cancer group and the healthy control have the ROC analysis result of 97.5 percent of specificity and 17.5 percent of sensitivity (figure 2); the Tetraspanin-14 protein in the plasma exosome can be shown to specifically distinguish lung cancer from healthy control.
The results show that the level difference of the Tetraspin-14 protein in the plasma exosomes of the lung cancer patients and the non-lung cancer patients is obvious, and the aim of screening the lung cancer can be fulfilled by detecting the level of the Tetraspin-14 protein in the plasma exosomes.
Example 2 composition of the detection kit of the invention and methods of use thereof
Kit composition
Detection kit (14 persons):
the reagent for preparing the plasma exosome protein needs to be self-prepared, and can be a commercial plasma exosome protein extraction kit.
Second, kit using method
The same as in the third section of example 1.
The kit can screen the risk of lung cancer of a human to be detected by detecting the level of the Tetrasmanin-14 protein in the plasma exosome: if the level of Tetraspan-14 protein is high (relative to healthy people), the risk of lung cancer is high, and if the level of Tetraspan-14 protein is low, the risk of lung cancer is low. The method can be used for the auxiliary diagnosis of clinical lung cancer, provides effective basis for patients to take relevant treatment measures or decisions, and has good clinical application prospect.
SEQUENCE LISTING
<110> Sichuan university Hospital in western China
Application of <120> Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit
<130> GYKH1094-2020P0111925CC20JS038
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 11
<212> PRT
<213> Artificial sequence
<400> 1
Val Val Asn Thr Gln Cys Gly Tyr Asp Val Arg
1 5 10
Claims (10)
1. Application of a reagent for detecting Tetraspin-14 protein in preparation of a lung cancer screening kit.
2. The use according to claim 1, wherein the reagent for detecting the Tetraspanin-14 protein is a reagent for enzyme-linked immunosorbent assay.
3. The use according to claim 1, wherein the reagent for detecting the Tetraspanin-14 protein is a western blot reagent.
4. The use according to claim 1, wherein the reagent for detecting the Tetraspanin-14 protein is a reagent for a protein chip detection method.
5. The use according to any one of claims 1 to 4, wherein the reagent for detecting the Tetraspin-14 protein is a reagent for detecting the Tetraspin-14 protein in human plasma exosomes.
6. A lung cancer screening kit is characterized by comprising a reagent for detecting Tetrasmanin-14 protein.
7. The kit according to claim 6, wherein the reagent for detecting the Tetraspanin-14 protein is a reagent for enzyme-linked immunosorbent assay.
8. The kit of claim 6, wherein the reagent for detecting the Tetraspanin-14 protein is a western blot reagent.
9. The kit according to claim 6, wherein the reagent for detecting the Tetraspanin-14 protein is a reagent for a protein chip detection method.
10. The kit according to any one of claims 6 to 9, wherein the reagent for detecting the Tetraspanin-14 protein is a reagent for detecting the Tetraspanin-14 protein in human plasma exosomes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011311801.1A CN112433053A (en) | 2020-11-20 | 2020-11-20 | Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011311801.1A CN112433053A (en) | 2020-11-20 | 2020-11-20 | Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112433053A true CN112433053A (en) | 2021-03-02 |
Family
ID=74693239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011311801.1A Pending CN112433053A (en) | 2020-11-20 | 2020-11-20 | Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112433053A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852974A (en) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | Compositions and methods for treating and diagnosing cancer |
| CN103782174A (en) * | 2011-06-07 | 2014-05-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers for cancer |
| CN103874770A (en) * | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| EP3716986A1 (en) * | 2017-12-01 | 2020-10-07 | Cornell University | Nanoparticles and distinct exosome subsets for detection and treatment of cancer |
-
2020
- 2020-11-20 CN CN202011311801.1A patent/CN112433053A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852974A (en) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | Compositions and methods for treating and diagnosing cancer |
| CN103782174A (en) * | 2011-06-07 | 2014-05-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers for cancer |
| CN103874770A (en) * | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| EP3716986A1 (en) * | 2017-12-01 | 2020-10-07 | Cornell University | Nanoparticles and distinct exosome subsets for detection and treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| 苏超粤等: "外泌体作为肺癌诊断和预后生物学标志物的研究进展", 《临床检验杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110108877A (en) | FAM172A autoantibody detection reagent is preparing the purposes in screening lung cancer kit | |
| CN110456064B (en) | Application of SARS2 autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN112433054A (en) | Application of C9 protein detection reagent in preparation of lung cancer screening kit | |
| CN110596389B (en) | Application of ESRP1 autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110850088B (en) | Use of GTF2IRD2 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN113917147A (en) | Application of PEFL-1 detection reagent in preparation of lung cancer screening kit | |
| CN112415199A (en) | Application of CETP detection reagent in preparation of lung cancer screening kit | |
| CN110456067B (en) | The use of EHD2 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110412274A (en) | The use of C6ORF106 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN112433053A (en) | Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit | |
| CN110632312B (en) | The use of A1CF autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110873797B (en) | Use of FKBP8 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110749733B (en) | Application of TGIF2LY autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110850089B (en) | Application of SARS autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110456079B (en) | Application of TAPBP autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110632313B (en) | The use of CDPF1 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110596386B (en) | Application of EGFLAM autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110632306B (en) | Application of ENO2 autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110780073B (en) | Application of SPANXN3 autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110456061B (en) | Use of RUNDC3A autoantibody detection reagent in the preparation of lung cancer screening kit | |
| CN110632308B (en) | Application of CASP8 autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN112415198A (en) | Application of GP1BB detection reagent in preparation of lung cancer screening kit | |
| CN112394171A (en) | Application of fibronectin detection reagent in preparation of lung cancer screening kit | |
| CN110780072B (en) | Application of APOO autoantibody detection reagent in preparation of lung cancer screening kit | |
| CN110632317A (en) | Application of SAMHD autoantibody detection reagent in preparation of lung cancer screening kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210302 |
|
| RJ01 | Rejection of invention patent application after publication |